Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis
暂无分享,去创建一个
G. Hazlewood | A. Rosenberg | K. Duffy | C. Solarte | D. Levy | J. P. Pardo | M. Batthish | P. Miettunen | K. Gerhold | Chloe Gottlieb | B. Lang | N. Tehrani | G. Chédeville | R. Berard | E. Fortin | D. Rumsey | D. Piskin | J. Gardiner | Andrea Human | Marie‐Paule Morin | Hon Yan Ng | André Jastrzebski | Muhammed Dhalla | Christina Forest | Sabrina Morgenstern | Carlos Eduardo Solarte | H. Y. Ng
[1] B. Feldman,et al. Variations in Pediatric Rheumatology Workforce and Care Processes Across Canada , 2021, The Journal of Rheumatology.
[2] C. Barnabe,et al. Informing the Evidence to Decision Process with Health Equity Considerations: Demonstration from the Canadian Rheumatoid Arthritis Care Context. , 2021, Journal of clinical epidemiology.
[3] C. Barnabe,et al. Supporting Equity in Rheumatoid Arthritis Outcomes in Canada: Population-Specific Factors in Patient-Centered Care. , 2021, The Journal of rheumatology.
[4] Justine R. Smith,et al. Recommendations for the management of childhood juvenile idiopathic arthritis‐type chronic anterior uveitis , 2021, Clinical & experimental ophthalmology.
[5] G. Bertelsen,et al. Uveitis in Juvenile Idiopathic Arthritis: 18-year Outcome in the Population-based Nordic Cohort Study. , 2020, Ophthalmology.
[6] D. Goldstein,et al. Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease. , 2020, Ophthalmology.
[7] P. Quartier. Tocilizumab in patients with juvenile idiopathic arthritis-associated uveitis , 2020 .
[8] Ashley P Jones,et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial , 2020, The Lancet Rheumatology.
[9] K. Rahmani,et al. Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis , 2020, Orphanet Journal of Rare Diseases.
[10] R. Cimaz,et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis , 2020, Clinical Rheumatology.
[11] R. Schneider,et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis , 2019, Arthritis & rheumatology.
[12] C. Foster,et al. The Challenge of Pediatric Uveitis: Tertiary Referral Center Experience in the United States , 2019, Ocular immunology and inflammation.
[13] Sheila T. Angeles-Han,et al. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis–Associated and Idiopathic Chronic Anterior Uveitis , 2019, Arthritis care & research.
[14] B. Feldman,et al. Prospective Determination of the Incidence and Risk Factors of New‐Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort , 2019, Arthritis care & research.
[15] W. Armbrust,et al. Efficacy of High-Dose Methotrexate in Pediatric Non-Infectious Uveitis , 2018, Ocular immunology and inflammation.
[16] R. Cimaz,et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting , 2018, Pediatric Rheumatology.
[17] M. González-Gay,et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. , 2018, Clinical and experimental rheumatology.
[18] A. Heiligenhaus,et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative , 2018, Annals of the rheumatic diseases.
[19] C. Elie,et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis , 2017, Annals of the rheumatic diseases.
[20] G. Guyatt,et al. [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]. , 2018, Gaceta sanitaria.
[21] R. Cafferty,et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis , 2018, Clinical Rheumatology.
[22] M. Zetterberg,et al. Assessment of the outcome of ophthalmological screening for uveitis in a cohort of Swedish children with juvenile idiopathic arthritis , 2017, Acta ophthalmologica.
[23] T. Kivelä,et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. , 2017, Clinical and experimental rheumatology.
[24] Ashley P Jones,et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis , 2017, The New England journal of medicine.
[25] Alonso Carrasco-Labra,et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. , 2017, Journal of clinical epidemiology.
[26] S. Calleja-Antolín,et al. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies. , 2016, Ophthalmology.
[27] R. Cimaz,et al. Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis , 2016, The Journal of Rheumatology.
[28] Anne‐Mieke J. W. Haasnoot,et al. Impact of Juvenile Idiopathic Arthritis Associated Uveitis in Early Adulthood , 2016, PloS one.
[29] O. Kalashnikova,et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. , 2016, Clinical and experimental rheumatology.
[30] M. Zierhut,et al. Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood , 2015, British Journal of Ophthalmology.
[31] I. Foeldvari,et al. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry , 2015, Arthritis care & research.
[32] J. Kempen,et al. The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. , 2015, Ophthalmology.
[33] P. Meroni,et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis , 2015, British Journal of Ophthalmology.
[34] W. Muntean,et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response , 2015, Scandinavian journal of rheumatology.
[35] A. Heiligenhaus,et al. Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis , 2015, The Journal of Rheumatology.
[36] P. Meroni,et al. Long-term Treatment with Golimumab for Severe Uveitis , 2014, Ocular immunology and inflammation.
[37] Y. Buys,et al. The landscape of ophthalmologists in Canada: present and future. , 2013, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[38] P. Paudyal,et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. , 2013, Rheumatology.
[39] E. Haddad,et al. Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis , 2012, The Journal of Rheumatology.
[40] R. V. Van Gelder,et al. Efficacy and potential complications of difluprednate use for pediatric uveitis. , 2012, American journal of ophthalmology.
[41] C. Foster,et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis , 2011, Eye.
[42] D. Jabs,et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. , 2010, Ophthalmology.
[43] A. Heiligenhaus,et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis , 2010, British Journal of Ophthalmology.
[44] R. Cimaz,et al. Abatacept for severe anti–tumor necrosis factor α refractory juvenile idiopathic arthritis–related uveitis , 2010, Arthritis care & research.
[45] R. Saurenmann,et al. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. , 2010, Arthritis and rheumatism.
[46] J. G. Ryan,et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. , 2009, American journal of ophthalmology.
[47] J. Chládek,et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. , 2009, Clinical and experimental rheumatology.
[48] A. Heiligenhaus,et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis , 2009, Eye.
[49] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[50] A. Rothova,et al. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis. , 2007, American journal of ophthalmology.
[51] A. Heiligenhaus,et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. , 2007, Rheumatology.
[52] A. Heiligenhaus,et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis : Value and requirement for additional anti-inflammatory medication , 2007 .
[53] M. Zierhut,et al. Mycophenolate mofetil in the treatment of uveitis in children , 2006, British Journal of Ophthalmology.
[54] D. Levy,et al. Favorable response to high-dose infliximab for refractory childhood uveitis. , 2006, Ophthalmology.
[55] G. Ellis,et al. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. , 1999, Journal of pediatric ophthalmology and strabismus.
[56] D. Mock,et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. , 1993, The Journal of rheumatology.
[57] D. Musson,et al. An in vitro comparison of the permeability of prednisolone, prednisolone sodium phosphate, and prednisolone acetate across the NZW rabbit cornea. , 1992, Journal of ocular pharmacology.